Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) announced the completion of its first export of naturally derived psilocybin to the United Kingdom in support of a planned Phase 2 clinical trial. The shipment includes psilocybin biomass and finished 5 mg psilocybin capsules manufactured at the company’s GMP facility in Princeton, British Columbia.
The capsules use the same formulation currently prescribed to patients in Australia for treatment-resistant depression and were exported under authorization from Health Canada and the UK Home Office. The company noted that the products were cultivated, extracted and manufactured in-house under its Drug Establishment Licence, reinforcing its position as a vertically integrated GMP supplier supporting both regulated patient access programs and clinical research initiatives.
This milestone is significant for the psychedelic medicine industry, as it demonstrates the ability to navigate complex international regulatory frameworks for the export of controlled substances. For business leaders, it signals growing commercialization opportunities in the mental health therapeutics market, which is increasingly exploring psychedelic-assisted therapies for conditions like depression, PTSD, and anxiety.
Optimi Health is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada.
The company supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally. Products are currently prescribed to patients in Australia under the country’s Authorized Prescriber Scheme and accessible in Canada through the Special Access Program. This latest export to the UK expands Optimi's global reach and could pave the way for broader adoption of psilocybin-based treatments.
The implications for the industry are substantial. Successful completion of the Phase 2 trial could accelerate regulatory approvals in the UK and other jurisdictions, opening new markets for psychedelic therapies. For investors, Optimi's ability to execute cross-border shipments under strict regulatory oversight enhances its credibility as a reliable supplier in a nascent but rapidly evolving sector.
For more information, visit Optimi Health or optimi.net. The full press release can be accessed at https://ibn.fm/WLDHZ.
